Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Exenatide (Primary)
- Indications Heart failure; Type 2 diabetes mellitus
- Focus Pharmacodynamics
Most Recent Events
- 04 Sep 2020 Biomarkers information updated
- 31 Jul 2009 Actual initiation date (Jul 2009) added as reported by ClinicalTrials.gov.
- 31 Jul 2009 Planned end date changed from 1 Dec 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.